Fractyl Health reported positive six-month clinical results for its Revita weight maintenance procedure, meeting its clinical goal, but shares fell steeply after the announcement. The market reaction suggests investors are differentiating between early clinical endpoints and longer-term commercial or regulatory expectations. The Revita approach targets weight maintenance rather than weight loss alone, a strategic distinction in a competitive metabolic disease landscape. The stock movement highlights how clinical progress is increasingly judged against the path to pivotal trials, payer evidence, and scale. For the sector, the episode illustrates the volatility around mid-stage readouts when the next validation steps are not yet fully de-risked.